MK 0354
Alternative Names: MK-0354Latest Information Update: 16 Mar 2022
At a glance
- Originator Arena Pharmaceuticals
- Developer Arena Pharmaceuticals; Merck & Co
- Class Antihyperlipidaemics
- Mechanism of Action G protein-coupled receptor agonists; GPR109A receptor agonists; GPR109B receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Atherosclerosis; Cardiovascular disorders; Lipid metabolism disorders
Most Recent Events
- 11 Mar 2022 Arena Pharmaceuticals has been acquired and merged into Pfizer
- 25 Jan 2008 Discontinued - Preclinical for Undefined indication in USA (PO)
- 29 Sep 2006 Discontinued - Phase-II for Atherosclerosis in USA (PO)